| Coronary Interventions and Diagnostics | Lifetime | 181 | CN 1 | 99.43 |
| Cardiac Imaging and Diagnostics | Lifetime | 423 | CN 2 | 99.29 |
| Cardiovascular Function and Risk Factors | Lifetime | 491 | CN 5 | 99.11 |
| Coronary Artery Anomalies | Lifetime | 102 | CN 1 | 98.86 |
| Cardiac Fibrosis and Remodeling | Lifetime | 91 | CN 5 | 98.45 |
| COVID-19 Clinical Research Studies | Lifetime | 975 | CN 149 | 96.85 |
| Acute Myocardial Infarction Research | Lifetime | 530 | CN 4 | 98.41 |
| Cardiac Valve Diseases and Treatments | Lifetime | 964 | CN 5 | 98.24 |
| Cardiac Structural Anomalies and Repair | Lifetime | 676 | CN 4 | 98.14 |
| Antiplatelet Therapy and Cardiovascular Diseases | Lifetime | 435 | CN 8 | 98.05 |
| Mesenchymal stem cell research | Lifetime | 600 | CN 77 | 97.28 |
| Heart Failure Treatment and Management | Lifetime | 614 | CN 3 | 97.78 |
| Pericarditis and Cardiac Tamponade | Lifetime | 132 | CN 1 | 96.36 |
| Tissue Engineering and Regenerative Medicine | Lifetime | 647 | CN 68 | 96.73 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 567 | CN 25 | 96.53 |
| Signaling Pathways in Disease | Lifetime | 420 | CN 16 | 95.81 |
| Kawasaki Disease and Coronary Complications | Lifetime | 215 | CN 3 | 95.47 |
| Cardiac Ischemia and Reperfusion | Lifetime | 776 | CN 47 | 95.80 |
| Extracellular vesicles in disease | Lifetime | 936 | CN 332 | 94.02 |
| Cardiovascular Issues in Pregnancy | Lifetime | 902 | CN 8 | 94.09 |
| Cardiovascular Health and Risk Factors | Lifetime | 725 | CN 77 | 91.86 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 932 | CN 29 | 87.21 |
| Hydrogen's biological and therapeutic effects | Lifetime | 799 | CN 242 | 73.01 |
| Coronary Interventions and Diagnostics | 2021-2025 | 22 | CN 1 | 99.55 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 5 | CN 1 | 98.11 |
| Cardiac Ischemia and Reperfusion | 2021-2025 | 11 | CN 3 | 97.48 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 126 | CN 2 | 99.13 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 155 | CN 2 | 98.71 |
| Acute Myocardial Infarction Research | 2021-2025 | 101 | CN 2 | 98.18 |
| Antiplatelet Therapy and Cardiovascular Diseases | 2021-2025 | 96 | CN 8 | 97.41 |
| Cardiac Valve Diseases and Treatments | 2021-2025 | 379 | CN 5 | 97.51 |
| Signaling Pathways in Disease | 2021-2025 | 25 | CN 10 | 91.49 |
| Mitochondrial Function and Pathology | 2021-2025 | 282 | CN 33 | 93.52 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 623 | CN 26 | 95.78 |
| Cardiac Structural Anomalies and Repair | 2021-2025 | 424 | CN 12 | 95.28 |
| Cardiac Arrhythmias and Treatments | 2021-2025 | 570 | CN 13 | 95.49 |
| Inflammasome and immune disorders | 2021-2025 | 275 | CN 138 | 91.34 |
| Peptidase Inhibition and Analysis | 2021-2025 | 452 | CN 122 | 91.94 |
| Infective Endocarditis Diagnosis and Management | 2021-2025 | 483 | CN 7 | 93.74 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 684 | CN 11 | 93.02 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 435 | CN 67 | 88.44 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 519 | CN 36 | 90.80 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 458 | CN 65 | 88.50 |
| Peripheral Artery Disease Management | 2021-2025 | 500 | CN 11 | 89.39 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 228 | CN 15 | 86.66 |
| Ubiquitin and proteasome pathways | 2021-2025 | 664 | CN 298 | 84.83 |
| Autophagy in Disease and Therapy | 2021-2025 | 905 | CN 437 | 82.56 |
| Pulmonary Hypertension Research and Treatments | 2021-2025 | 992 | CN 134 | 84.34 |
| Tissue Engineering and Regenerative Medicine | 2021-2025 | 902 | CN 279 | 81.26 |
| Sirtuins and Resveratrol in Medicine | 2021-2025 | 237 | CN 65 | 78.20 |
| Congenital heart defects research | 2021-2025 | 635 | CN 89 | 76.74 |
| Cancer-related gene regulation | 2021-2025 | 997 | CN 678 | 75.93 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 931 | CN 198 | 75.30 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 650 | CN 135 | 73.68 |
| Nitric Oxide and Endothelin Effects | 2021-2025 | 382 | CN 95 | 70.68 |
| Lipid metabolism and disorders | 2021-2025 | 653 | CN 175 | 66.86 |
| Cardiovascular, Neuropeptides, and Oxidative Stress Research | 2021-2025 | 239 | CN 60 | 64.83 |
| ATP Synthase and ATPases Research | 2021-2025 | 700 | CN 94 | 63.11 |
| Cardiac and Coronary Surgery Techniques | 2021-2025 | 934 | CN 109 | 62.74 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 873 | CN 191 | 57.04 |
| Coenzyme Q10 studies and effects | 2021-2025 | 192 | CN 20 | 56.89 |
| Cell death mechanisms and regulation | 2021-2025 | 845 | CN 251 | 45.78 |
| Apelin-related biomedical research | 2021-2025 | 621 | CN 133 | 41.22 |
| Heart rate and cardiovascular health | 2021-2025 | 242 | CN 41 | 33.95 |
